Trials & Tribulations Of adaptive and factorial designsA biostatistician’s interpretation of last week’s ODAC August 02, 2024Vol.50 No.31By Donald A. Berry
Trials & Tribulations Better oncology drug management could lead to improved outcomes, lower costs July 26, 2024Vol.50 No.30By Matt Ingram
Trials & Tribulations The thorny road to drug approval for myelodysplastic syndromes June 14, 2024Vol.50 No.24By Mikkael A. Sekeres
Trials & Tribulations Paired tumor-germline testing can enhance patient care—with guidance from genetics specialists June 07, 2024Vol.50 No.23By Rebecca Sutphen
Trials & Tribulations Are we focused on the wrong risk type in genetic screening?Breast cancer screening study shows new paths to population screening May 24, 2024Vol.50 No.21By Cassie Hajek
Trials & Tribulations Single-cell based precision oncology: First steps in addressing and overcoming tumor heterogeneity May 10, 2024Vol.50 No.19By Sanju Sinha and Eytan Ruppin
Trials & Tribulations Canine cancers as models: We have barely tapped the full potential of comparative oncology May 03, 2024Vol.50 No.18By Christina K. Lopes
Trials & Tribulations A new standard in cancer care: Integrated screening, stepped collaborative care for common and distressing symptoms April 05, 2024Vol.50 No.14By Jennifer A. Steel
Trials & Tribulations Cancer AI systems: We need oncologists to help us build trusted models March 01, 2024Vol.50 No.09By Bernard Chien
Trials & Tribulations Florez Laboratory at Dana-Farber launches International Pregnancy and Lung Cancer Registry February 09, 2024Vol.50 No.06By Narjust Florez, Lauren Keil, Rebekah Kaufman and Oyepeju Abioye-Akintola
